This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Petri, M Search for Related Content PubMed PubMed Citation Articles by Petri, M Social Bookmarking                         What's this?

Exogenous estrogen in systemic lupus erythematosus: oral contraceptives and hormone replacement therapy

Johns Hopkins University School of Medicine, 1830 East Monument Street, Suite 7500, Baltimore, MA 21205, USA, Fax: / 1 410 614 0498; mpetri{at}welch.jhu.edu

The role of exogenous estrogen in the initiation and maintenance of human SLE remains very controversial. Although cohort studies suggest an increase in the incidence of SLE with both oral contraceptives and hormone replacement therapy, recent retrospective studies suggest that the risk of flare is not increased with hormone replacement therapy. However, exogenous estrogen does increase hypercoagulability, an issue in SLE patients with antiphospholipid antibodies. The prospective SELENA study will ultimately address whether exogenous estrogen increases severe flares in SLE.

Key Words: SLE • oral contraceptives • hormone replacement therapy

Lupus, Vol. 10, No. 3, 222-226 (2001)
DOI: 10.1191/096120301676707393


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				C C Mok and C S Lau Pathogenesis of systemic lupus erythematosus J. Clin. Pathol., July 1, 2003; 56(7): 481 - 490. [Abstract] [Full Text] [PDF]